Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: Stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?

Diabetes Research and Clinical Practice

Volumn 106, Issue 1, 2014, Pages e3-e6

  Wu, Tongzhi ^a   Thazhath, Sony S ^a   Bound, Michelle J ^a   Jones, Karen L ^a   Horowitz, Michael ^a   Rayner, Christopher K ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Dipeptidyl peptidase 4; Enteral nutrition; Glucagon like peptide 1; Metformin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; METFORMIN; PLACEBO; ANTIDIABETIC AGENT; DPP4 PROTEIN, HUMAN; GLUCOSE BLOOD LEVEL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME RELEASE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; ANALYSIS; BLOOD; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SECRETION (PROCESS);

BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84907970634     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.08.004     Document Type: Article

References (16)

1. Migoya E.M., Bergeron R., Miller J.L., Snyder R.N., Tanen M., Hilliard D., et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010, 88:801-808.
2. Wu T., Ma J., Bound M.J., Checklin H., Deacon C.F., Jones K.L., et al. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans, and patients with type 2 diabetes treated with or without metformin. Diabetes 2014, 10.2337/DB13-1627.
3. Hinke S.A., Kuhn-Wache K., Hoffmann T., Pederson R.A., McIntosh C.H., Demuth H.U. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002, 291:1302-1308.
4. Cuthbertson J., Patterson S., O'Harte F.P., Bell P.M. Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in type 2 diabetes. Diabet Med 2009, 26:649-654.
5. Green B.D., Irwin N., Duffy N.A., Gault V.A., O'Harte F.P., Flatt P.R. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 2006, 547:192-199.
6. Lindsay J.R., Duffy N.A., McKillop A.M., Ardill J., O'Harte F.P., Flatt P.R., et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes. Diabet Med 2005, 22:654-657.
7. Nagakura T., Yasuda N., Yamazaki K., Ikuta H., Tanaka I. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metabolism 2003, 52:81-86.
8. Durinx C., Lambeir A.M., Bosmans E., Falmagne J.B., Berghmans R., Haemers A., et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 2000, 267:5608-5613.
9. Bland J.M., Altman D.G. Calculating correlation coefficients with repeated observations: part 1-correlation within subjects. Br Med J 1995, 310:446.
10. Mulherin A.J., Oh A.H., Kim H., Grieco A., Lauffer L.M., Brubaker P.L. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 2011, 152:4610-4619.
11. Lenhard J.M., Croom D.K., Minnick D.T. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Commun 2004, 324:92-97.
12. Cho Y.M., Kieffer T.J. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia 2011, 54:219-222.
13. Busso N., Wagtmann N., Herling C., Chobaz-Peclat V., Bischof-Delaloye A., So A., et al. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol 2005, 166:433-442.
14. Itou M., Kawaguchi T., Taniguchi E., Sata M. Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol 2013, 19:2298-2306.
15. Firneisz G., Varga T., Lengyel G., Feher J., Ghyczy D., Wichmann B., et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One 2010, 5:e12226.
16. Balaban Y.H., Korkusuz P., Simsek H., Gokcan H., Gedikoglu G., Pinar A., et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 2007, 6:242-250.